Expression of the HPV11 E2 gene in transgenic mice does not result in alterations of the phenotypic pattern.
The E2 early protein of human papillomaviruses (HPV) has been found associated with the mitotic spindle therefore being implicated in the partition of the replicated viral DNA to daughter cells. In addition, E2 proteins bind to the upstream regulatory region of the virus and to cellular promoters modulating thereby cellular transcription and differentiation. In many cervical cancers, the E2 reading frame is interrupted upon incorporation of the viral genome into the host DNA. This results in the loss of the E2 mediated transcriptional repression and uncontrolled expression of the viral oncogenes. All these results have been obtained in transfected cells but no information is available on the E2 effects in the context of the entire organism. Transgenic mice were generated expressing the E2 protein of HPV11 under the control of the Ubiquitin C promoter. E2 mRNA is present in all mice tissues analysed and the E2 protein expressed in the skin (the target tissue of HPV11) was shown by Western blotting, albeit at a very low level. Analysis of the transgenic mice shows no major histological changes in the skin or all other tissues investigated. These data indicate that in transgenic mice the human papillomavirus type 11 E2 does not grossly modulate cellular proliferation or differentiation events.
Leykauf
Kerstin
K
German Cancer Research Centre, Heidelberg, F050, Im Neuenheimer Feld 280, Heidelberg, 69120, Germany.
Kabsch
Kirsten
K
Gassler
Nikolaus
N
Gissmann
Lutz
L
Alonso
Angel
A
Schenkel
Johannes
J
D000818:Animals; D001483:Base Sequence; D017931:DNA Primers / Q000235:genetics; D005260:Female; D015870:Gene Expression; D005814:Genes, Viral; D052140:Human papillomavirus 11 / Q000235:genetics* / Q000472:pathogenicity; D006801:Humans; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D010641:Phenotype; D011401:Promoter Regions, Genetic; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012367:RNA, Viral / Q000235:genetics / Q000378:metabolism; D011994:Recombinant Proteins / Q000235:genetics; D012867:Skin / Q000378:metabolism / Q000473:pathology / Q000821:virology; D025822:Ubiquitin C / Q000235:genetics; D014764:Viral Proteins / Q000235:genetics*
D017931:DNA Primers; C117355:E2 protein, Human papillomavirus type 11; D012333:RNA, Messenger; D012367:RNA, Viral; D011994:Recombinant Proteins; D025822:Ubiquitin C; D014764:Viral Proteins
Biochemistry. 1999 Apr 6;38(14):4586-94
10194380
Oncogene. 2003 Jan 16;22(2):168-75
12527886
Semin Cancer Biol. 1996 Dec;7(6):339-47
9284526
J Virol. 2004 Oct;78(19):10738-46
15367640
J Cell Sci. 2006 Sep 1;119(Pt 17):3634-42
16931598
Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4030-5
15020762
Int J Oncol. 2000 May;16(5):853-70
10762621
Cancer Res. 2005 Feb 15;65(4):1394-400
15735026
Brain Res Mol Brain Res. 2002 Aug 15;104(2):194-202
12225874
J Virol. 2007 Feb;81(4):1736-45
17135315
J Biol Chem. 2003 Jul 18;278(29):26765-72
12730224
Nucleic Acids Res. 1996 May 1;24(9):1787-8
8650001
J Virol. 2001 Aug;75(16):7244-51
11461997
Mol Pathol. 1999 Oct;52(5):275-82
10748877
Virus Res. 2005 Nov;113(2):81-8
15913825
Cell Cycle. 2005 Nov;4(11):1608-15
16222116
J Virol. 1998 Oct;72(10):8115-23
9733852
J Virol. 2006 May;80(10):4792-800
16641272
J Virol. 2006 May;80(9):4580-90
16611918
Int J Gynecol Pathol. 1998 Apr;17(2):146-53
9553812
Annu Rev Microbiol. 1994;48:427-47
7826013
Nucleic Acids Res. 1992 Jan 25;20(2):251-6
1311070
Endocrinology. 2002 Oct;143(10):4084-95
12239120
Microbiol Mol Biol Rev. 2004 Jun;68(2):362-72
15187189
J Biol Chem. 2005 Oct 28;280(43):36088-98
16135518
Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2930-5
8610145
J Virol. 1994 Feb;68(2):1115-27
8289341
Curr Opin Genet Dev. 2005 Oct;15(5):515-9
16099158
Biochimie. 2003 Aug;85(8):813-9
14585548
J Virol. 2003 May;77(9):5253-65
12692227
J Virol. 2000 Oct;74(19):9090-8
10982355
J Invest Dermatol. 1999 Jun;112(6):893-8
10383735
J Gen Virol. 2005 May;86(Pt 5):1307-13
15831941
J Virol. 1987 Apr;61(4):962-71
3029430
FASEB J. 2004 Aug;18(11):1243-5
15180960